© 2000 American Heart Association, Inc.
Editorials |
Metabolic Mechanisms Associated With Antianginal Therapy
From the Metabolic Research Laboratory, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Mass.
Correspondence to E. Douglas Lewandowski, PhD, Department of Radiology, Room 2301, Massachusetts General Hospital, Bldg 149, 13th St, Charlestown, MA 02129. E-mail doug@nmr.mgh.harvard.edu
Key Words: myocardial ischemia • fatty acids • mitochondria • glycolysis • metabolism
 |
Introduction |
|---|
Laboratory investigations into preserving viability of the ischemic myocardium or to promote recovery during reperfusion have often focused on the intermediary pathways of energy metabolism. However, in the clinical treatment of angina, the application of metabolic therapies has generally lagged behind or has been incidental to other approaches, such as a vasodilators, calcium antagonists, and negative inotropes. A study published in this issue of Circulation Research has demonstrated that the antianginal agent trimetazidine (1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride [TMZ]) inhibits the activity of one of the enzymes of the ß-oxidation pathway in cardiac mitochondria with direct increases in glucose oxidation.1 These findings confirm in an intact, functioning heart model the well-documented, anti-ischemic properties of TMZ2 3 4 and the inhibitory effects of TMZ on long-chain fatty acid oxidation5 with reciprocal enhancement of glucose uptake.6 The study localizes the inhibition of ß-oxidation to a specific enzyme, the mitochondrial long-chain 3-ketoacyl coenzyme A (CoA) thiolase. The suggestion by the authors is that the effectiveness of TMZ as an antianginal agent is directly linked to this inhibitory effect on long-chain fatty acid oxidation.
Although studies on the isolated heart preparation can neither
specifically nor conclusively identify an antianginal mechanism, the
findings of the University of Alberta group1 are
consistent with the known effectiveness of TMZ as an
antianginal agent7 8 9 that reduces long-chain fatty acid
oxidation, while lacking both vasodilator activity and negative
inotropic effects.9 The inhibitory effects of
TMZ on long-chain fatty acid transport into rat heart mitochondria, via
inhibition of carnitine palmitoyltransferase 1 (CPT 1) enzyme,
This article has been cited by other articles:
 |
|
 |
|
  W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. N. Chavez, W. C. Stanley, T. A. McElfresh, H. Huang, J. P. Sterk, and M. P. Chandler Effect of hyperglycemia and fatty acid oxidation inhibition during aerobic conditions and demand-induced ischemia Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1521 - H1527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Kudej, L. T. White, A. B. Kudej, S. F. Vatner, and E. D. Lewandowski Brief Increase in Carbohydrate Oxidation After Reperfusion Reverses Myocardial Stunning in Conscious Pigs Circulation, November 26, 2002; 106(22): 2836 - 2841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Rottman, D. Bracy, C. Malabanan, Z. Yue, J. Clanton, and D. H. Wasserman Contrasting effects of exercise and NOS inhibition on tissue-specific fatty acid and glucose uptake in mice Am J Physiol Endocrinol Metab, July 1, 2002; 283(1): E116 - E123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Lewandowski, R. K. Kudej, L. T. White, J. M. O'Donnell, and S. F. Vatner Mitochondrial Preference for Short Chain Fatty Acid Oxidation During Coronary Artery Constriction Circulation, January 22, 2002; 105(3): 367 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Chandler, H. Huang, T. A. McElfresh, and W. C. Stanley Increased nonoxidative glycolysis despite continued fatty acid uptake during demand-induced myocardial ischemia Am J Physiol Heart Circ Physiol, May 1, 2002; 282(5): H1871 - H1878. [Abstract] [Full Text] [PDF]
|
|